

11-10-04
675'92'37

C-off

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/807,802	
	Filing Date	November 29, 2001	
	First Named Inventor	James M. Wilson	
	Art Unit	1635	
	Examiner Name	Brian A. Whiteman	
Total Number of Pages in This Submission	41	Attorney Docket Number	GNV31AUSA

Certificate
NOV 15 2004
of Correction

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	3 pp. Request for Certificate of correction under 35 USC Section 254
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	3 pp. PTO/SB/44 form
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	28pp. Copies of original spec. pages, examiners Amendment, examiners cited references, Response and IDS 6 pp. Copies of original patent pages marked in red Customer No. 00270 Express Mail No. ER635161526US	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	HOWSON AND HOWSON Cathy A. Kodroff
Signature	
Date	November 9, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NOV 19 2004



GNV31AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 09/807,802 Confirmation No.: 5849
Applicant : James M. Wilson et al
Filed : November 29, 2001
Patent No. : 6,759,237 B1
Issued : July 6, 2004
TC/A.U. : 1635
Examiner : Brian Whiteman
Customer No. : 00270
Title : ADENO-ASSOCIATED VIRUS SEROTYPE 1
NUCLEIC ACID SEQUENCES, VECTORS AND
HOST CELLS CONTAINING SAME

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 35 USC SECTION 254

The following errors were found in the above-identified patent:

- (1) Front page, add US Patent No. "5,622,856" under (56) references cited
- (2) Front page, under foreign patent documents, replace "WO03/983440" with -- WO03/093440 -- .

NOV 19 2004

- (3) Front page, under (57) Abstract, replace “An improved tet-repressible system is described in which the transgene is expressed under the control of a promoter which is activated upon binding of a fusion protein composed of a reverse tet repressor/activation domain to tet operator sequences located immediately upstream of the transgene promoter. The tet operator sequences are substantially free of interferon inducible response elements (ISRE). The reverse tet repressor is fused to an activation domain which lacks signals for protein clearance, thus extending expression of the fusion protein. Suitably, the tetO sequences are immediately upstream of a quiet promoter.”

with

-- The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors. -- .

- (4) Col. 3, lines 15-18, replace “FIG. 2 illustrates the predicted secondary structure of AAV-1 ITR has been inserted after the word. The nucleotides in AAV-2 and AAV-6 are shown in italic and bold respectively”

with

-- FIG. 2 illustrates the predicted secondary structure of AAV-1 ITR nucleotides 1-143 of SEQ ID NO. 1. The nucleotides in AAV-2 and AAV-6 are shown in italic and bold respectively. -- .

- (5) Col. 3, line 25-29, replace “FIG. 3B is a detailed illustration of a 71 bp homologous region among AAV-1 has been inserted after the word, AAV-2 has been inserted after the word and AAV-6 has been inserted after the word. Nucleotides that differ among these serotypes are indicated by arrows.”

with

-- FIG. 3B is a detailed illustration of a 71 bp homologous region among AAV-1 nucleotides 438-531 of SEQ ID NO: 1, AAV-2 nucleotides 424-517 of SEQ ID NO: 18, and AAV-6 nucleotides 423-516 of SEQ ID NO: 19. Nucleotides that differ among these serotypes are indicated by arrows. -- .

- (6) Col. 8, line 53, replace “vivo,” with -- vitro, -- .
- (7) Col. 9, line 47, replace “sued” with -- used -- .
- (8) Col. 18, line 28, replace “(5x10¹ genomes)” with -- (5x10¹⁰ genomes) -- .
- (9) Col. 91, line 48, replace “arc” with -- are -- .

It is requested that a Certificate of Correction be issued to correct the above errors in accordance with the enclosed Form PTO 1050, which is submitted herewith.

These errors are typographical in nature and make no substantive changes. All errors were made by the USPTO, no fee is due for correction of these errors.

Enclosed for each correction is a photocopy of the original specification pages, examiners amendment, examiners cited reference, response and an IDS with the relevant words or phrases highlighted in blue and the corresponding original patent with errors marked in red. These documents will support the USPTO errors.

The Director of the US Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON AND HOWSON

Attorneys for the Applicants

BY 
Cathy A. Kodroff


Registration No. 33,980

Spring House Corporate Center
Box 457

Spring House, PA 19477

Telephone: (215) 540-9210

Telefacsimile: (215) 540-5818



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00

Complete if Known

Application Number	09/807,802
Filing Date	November 29, 2001
First Named Inventor	James M. Wilson
Examiner Name	Brian A. Whiteman
Art Unit	1635
Attorney Docket No.	GNV31AUSA/UPNK1774

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 08-3040

Deposit Account Name HOWSON AND HOWSON

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
9	-20** = 0	X 0 = 0	
1	-3** = 0	X 0 = 0	
Multiple Dependent		0 = 0	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	180.00
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00

(Complete if applicable)

SUBMITTED BY		Registration No.	33,980	Telephone	215-540-9200
Name (Print/Type)	Cathy A. Kodroff	(Attorney/Agent)		Date	December 23, 2003
Signature					

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EXPRESS MAIL NO. EU 531571956US

CUSTOMER NO. 00270

NOV 19 2004



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/807,802	
	Filing Date	November 29, 2001	
	First Named Inventor	James M. Wilson	
	Group Art Unit	1635	
	Examiner Name	Brian A. Whiteman	
Total Number of Pages in this Submission	14	Attorney Docket Number	GNV31AUSA/UPN-K1774

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 12-References
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	HOWSON AND HOWSON Cathy A. Kodroff
Signature	
Date	December 23, 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name			
Signature		Date	


This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EXPRESS MAIL NO. EU531571956US

CUSTOMER NO. 00270

NOV 19 2004



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

PTO/SB/44 (04-04)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,759,237 ^{B1}
DATED : July 6, 2004
INVENTOR(S) : James M. Wilson and Weidong Xiao

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (1) Front page, add US Patent No. "5,622,856" under (56) references cited
 - (2) Front page, under foreign patent documents, replace "WO03/983440" with -- WO03/093440 -- .
 - (3) Front page, under (57) Abstract, replace "An improved tet-repressible system is described in which the transgene is expressed under the control of a promoter which is activated upon binding of a fusion protein composed of a reverse tet repressor/activation domain to tet operator sequences located immediately upstream of the transgene promoter. The tet operator sequences are substantially free of interferon inducible response elements (ISRE). The reverse tet repressor is fused to an activation domain which lacks signals for protein clearance, thus extending expression of the fusion protein. Suitably, the tetO sequences are immediately upstream of a quiet promoter."
- with
- The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors. -- .

MAILING ADDRESS OF SENDER:

HOWSON AND HOWSON
Spring House Corporate Center
Box 457
Spring House, PA 19477

PATENT NO: 6,759,237

No. of additional copies

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any US Patent and Trademark Office, US Department of commerce, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Correction Branch, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

NOV 19 2004

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO : 6,759,237 B1
DATED : July 6, 2004
INVENTOR(S) : James M. Wilson and Weidong Xiao

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (4) Col. 3, lines 15-18, replace "FIG. 2 illustrates the predicted secondary structure of AAV-1 ITR has been inserted after the word. The nucleotides in AAV-2 and AAV-6 are shown in italic and bold respectively"

with

-- FIG. 2 illustrates the predicted secondary structure of AAV-1 ITR nucleotides 1-143 of SEQ ID NO. 1. The nucleotides in AAV-2 and AAV-6 are shown in italic and bold respectively. -- .

- (5) Col. 3, line 25-29, replace "FIG. 3B is a detailed illustration of a 71 bp homologous region among AAV-1 has been inserted after the word, AAV-2 has been inserted after the word and AAV-6 has been inserted after the word. Nucleotides that differ among these serotypes are indicated by arrows."

with

-- FIG. 3B is a detailed illustration of a 71 bp homologous region among AAV-1 nucleotides 438-531 of SEQ ID NO: 1, AAV-2 nucleotides 424-517 of SEQ ID NO: 18, and AAV-6 nucleotides 423-516 of SEQ ID NO: 19. Nucleotides that differ among these serotypes are indicated by arrows. -- .

MAILING ADDRESS OF SENDER:

HOWSON AND HOWSON
Spring House Corporate Center
Box 457
Spring House, PA 19477

PATENT NO: 6,759,237

No. of additional copies

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any US Patent and Trademark Office, US Department of commerce, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Correction Branch, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

NOV 19 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,759,237 B1
DATED : July 6, 2004
INVENTOR(S) : James M. Wilson and Weidong Xiao

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (6) Col. 8, line 53, replace "vivo," with -- vitro, -- .
- (7) Col. 9, line 47, replace "sued" with -- used -- .
- (8) Col. 18, line 28, replace "(5x10¹ genomes)" with -- (5x10¹⁰ genomes) -- .
- (9) Col. 91, line 48, replace "arc" with -- are -- .

MAILING ADDRESS OF SENDER:

HOWSON AND HOWSON
Spring House Corporate Center
Box 457
Spring House, PA 19477

PATENT NO: 6,759,237

No. of additional copies

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any US Patent and Trademark Office, US Department of commerce, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Correction Branch, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

NOV 19 2004



US006759237B1

(12) **United States Patent**
Wilson et al.

(10) **Patent No.:** US 6,759,237 B1
(45) **Date of Patent:** Jul. 6, 2004

(54) **ADENO-ASSOCIATED VIRUS SEROTYPE 1
NUCLEIC ACID SEQUENCES, VECTORS
AND HOST CELLS CONTAINING SAME**

WO WO01/83692 A2 11/2001
WO WO03/092598 A2 11/2003
WO WO03/983440 A2 11/2003

See attached
S.I.D.S. - 12-23-03

(75) **Inventors:** James M. Wilson, Gladwyne, PA (US);
Weidong Xiao, Fort Washington, PA (US)

(73) **Assignee:** The Trustees of the University of
Pennsylvania, Philadelphia, PA (US)

(*) **Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** 09/807,802

(22) **PCT Filed:** Nov. 2, 1999

(86) **PCT No.:** PCT/US99/25694

§ 371 (c)(1),
(2), (4) **Date:** Nov. 29, 2001

(87) **PCT Pub. No.:** WO00/28061

PCT Pub. Date: May 18, 2000

Related U.S. Application Data

(60) **Provisional application No.** 60/107,114, filed on Nov. 5,
1998.

(51) **Int. Cl.⁷** C12N 15/00; C12N 15/09;
C12N 15/63; C12N 15/864; C12N 15/70;
C12N 15/74

(52) **U.S. Cl.** 435/320.1; 435/456; 435/325;
435/366; 435/367; 424/93.2

(58) **Field of Search** 435/320.1, 455,
435/456, 325, 20.1; 424/93.21, 93.2; 576/23.72

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,871,982 A 2/1999 Wilson 435/172.3
6,156,303 A * 12/2000 Russell et al. 424/93.2
6,251,677 B1 6/2001 Wilson 435/457
6,258,595 B1 7/2001 Gao 435/320.1
6,274,354 B1 8/2001 Wilson 435/91.42
6,365,394 B1 4/2002 Gao et al. 435/239
6,387,368 B1 5/2002 Wilson et al. 424/93.2
6,399,385 B1 6/2002 Croyle et al. 435/456
6,475,769 B1 11/2002 Wilson et al. 435/235.1
6,482,634 B1 11/2002 Wilson et al. 435/235.1

FOREIGN PATENT DOCUMENTS

WO WO96/13598 A2 5/1996
WO WO 9613598 * 5/1996
WO WO98/10086 A1 3/1998
WO WO98/10088 A1 3/1998
WO WO98/11244 A2 3/1998
WO WO99/14354 A1 3/1999
WO WO99/15677 A1 4/1999
WO WO99/15685 A1 4/1999
WO WO99/47691 A1 9/1999
WO WO00/55342 A1 9/2000
WO WO00/75353 A1 12/2000
WO WO01/23001 A2 4/2001
WO WO01/23597 A2 4/2001
WO WO01/40455 A2 6/2001

OTHER PUBLICATIONS

Rose et al., Microbiology, vol. 546, 1966, pp. 86-92.*
Anderson et al., Nature, vol. 392, pp. 25-30, 1998.*
Verma, Nature, vol. 389, pp. 239-242, 1997.*
Orkin et al., "Report and Recommendations of the Panel to
Assess the NIH Investments in Research on Gene Therapy",
issue by the National Institute of Health, Dec. 7, 1995.*
Hauck et al, Generation and Characterization of Chimeric
Recombinant AAV Vectors, Molecular Therapy, vol. 7, No.
3, pp. 419-425, (Mar. 2003).
Rabinowitz et al, Cross-Packaging of a Single Adeno-As-
sociated Virus (AAV) Type 2 Vector Genome into Multiple
AAV Serotypes Enables Transduction with Broad Specific-
ity, Journal of Virology, vol. 76, No. 2, pp. 791-801, (Jan.
2000).
Hauck et al, Characterization of Tissue Tropism Determi-
nants of Adeno-Associated Virus Type 1, Journal of Virol-
ogy, vol. 77, No. 4, pp. 2768-2774, (Feb. 2003).
Arruda et al, Safety and Efficacy of Factor IX Gene Transfer
to Skeletal Muscle in Murine and Canine Hemophilia B
Models by Adeno-Associated Viral Vector Serotype 1,
Blood First Edition Paper, (Sep. 11, 2003).
E. Rutledge et al, "Infectious Clones and Vectors Derived
from Adeno-Associated Virus (AAV) Serotypes Other Than
AAV Type 2", Journal of Virology, 72(1):309-319 (Jan.,
1998).
W. Xiao et al, "Gene Therapy Vectors Based on Adeno-As-
sociated Virus Type 1", Journal of Virology,
73(5):3994-4003 (May, 1999).
H. Chao et al, "Several Log Increase in Therapeutic Trans-
gene Delivery by Distinct Adeno-Associated Viral Serotype
Vectors", Molecular Therapy, 2(6):619-623 (Dec., 2000).
R. Kotin et al, "Site-Specific integration by Adeno-Asso-
ciated Virus", Proc. Natl. Acad. Sci. USA, 87:2211-2215
(Mar., 1990).
K. Fisher et al, "Recombinant Adeno-Associated Virus for
Muscle Directed Gene Therapy", Nature Medicine,
3(3):306-312 (Mar., 1997).

(List continued on next page.)

Primary Examiner—Scott D. Priebe

Assistant Examiner—Brian Whiteman

(74) **Attorney, Agent, or Firm**—Howson and Howson

(57) **ABSTRACT**

An improved tet-repressible system is described in which the transgene is expressed under the control of a promoter which is activated upon binding of a fusion protein composed of a reverse tet repressor/activation domain to tet operator sequences located immediately upstream of the transgene promoter. The tet operator sequences are substantially free of interferon inducible response elements (ISRE). The reverse tet repressor is fused to an activation domain which lacks signals for protein clearance, thus extending expression of the fusion protein. Suitably, the tetO sequences are immediately upstream of a quiet promoter.

See attached
Response
dated 12-23-03
with label pasted



ERROR (1)

Notice of References Cited

Application/Control No. 09/807,802		Applicant(s)/Patent Under Reexamination WILSON ET AL.	
Examiner Brian Whiteman		Art Unit 1635	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-5,622,856	04-1997	Natsoulis	435/325
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Rutledge et al., Virol 1998; 72:309-19
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



GNV31AUSA/UPN-K1774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of
James M. Wilson

Appln. No. 09/807,802

Filed: November 29, 2001

For: ADENO-ASSOCIATED VIRUS
SEROTYPE I NUCLEIC ACID
SEQUENCES, VECTORS AND HOST
CELLS CONTAINING SAME

) Group Art Unit: 1635
)
) Examiner: Brian A. Whiteman
)
) Confirmation No. 5849
)
)
)
)
)
) December 23, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and a copy of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and after the receipt of a first Office Action on the merits. Therefore, a fee of \$180.00 is due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.


EXPRESS MAIL NO. EU531571956US

CUSTOMER NO. 00270

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By 
Cathy A. Kodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Phone: (215) 540-9200
Fax: (215) 540-5818



PTO/SB/08B (04-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/807,802
				Filing Date	April 17, 2001
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
Examiner Name	Brian A. Whiteman				
Attorney Docket Number	GNV31AUSA/UPN-K1774				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	CA	US-6,387,368 B1	05-14-2002	Wilson et al	
	CB	US-6,274,354 B1	08-14-2001	Wilson et al	
	CC	US-6,482,634 B1	11-19-2002	Wilson et al	
	CD	US-6,475,769 B1	11-05-2002	Wilson et al	
	CE	US-6,365,394 B1	04-02-2002	Gao et al	
	CF	US-6,399,385 B1	06-04-2002	Croyle et al	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ <i>(if known)</i>					
	CG	PCT WO03/093440	A2	11-13-2003	University of Florida		
	CH	PCT WO03/092598	A2	11-13-2003	University of Florida		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
PTO/SB/08B (08-00)



Approved for use
through 4/30/2003.
OMB 0651-0031

U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/807,802
				Filing Date	April 17, 2001
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	2	of	2	Attorney Docket Number	GNV31AUSA/UPN-K1774

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column(s), volume(s), publisher, city and/or country where published	T ²
	CI	HAUCK ET AL, Generation and Characterization of Chimeric Recombinant AAV Vectors, Molecular Therapy, Vol. 7, No. 3, pp. 419-425, (March 2003)	
	CJ	RABINOWITZ ET AL, Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2002)	
	CK	HAUCK ET AL, Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 77, No. 4, pp. 2768-2774, (February 2003)	
	CL	ARRUDA ET AL, Safety and Efficacy of Factor IX Gene Transfer to Skeletal Muscle in Murine and Canine Hemophilia B Models by Adeno-Associated Viral Vector Serotype 1, Blood First Edition Paper, (September 11, 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



GNVPM.031 USA
09/807,802

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1635
)
James M. Wilson et al) Examiner: B. Whiteman
)
Appln. No. 09/807,802) Confirmation No. 5849
)
Filed: November 29, 2001)
)
For: ADENO-ASSOCIATED VIRUS) December 23, 2003
SEROTYPE I NUCLEIC ACID)
SEQUENCES, VECTORS AND HOST)
CELLS CONTAINING SAME)

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE PURSUANT TO 37 CFR 1.111

Sirs:

This is in timely response to the Office Action dated September 25, 2003.
Kindly amend the application as follows.

In the Specification:

Add the attached abstract of the disclosure, provided herewith on a separate sheet.

Other specification amendments are provided on a separate sheet.

In the Claims:

Claims 9, 10, 11, 14, 17, 18, 19, 20, 29, 30 and 37-40 are cancelled, without prejudice. Kindly add new claims 41 – 45 as follows.

Amendments to the Specification:

Kindly replace the paragraph at page 12, lines 15 – 26, with the following:

- -

Alternatively, the cis plasmid and, optionally, the trans plasmid, may be transfected into a packaging cell line which provides the remaining helper functions necessary for production of a rAAV containing the desired AAV-1 sequences of the invention. An example of a suitable packaging cell line, wherein an AAV=2 capsid is desired, is B-50, which stably expresses AAV-2 rep and cap genes under the control of a homologous P5 promoter. This cell line is characterized by integration into the cellular chromosome of multiple copies (at least 5 copies) of P5-rep-cap gene in a concatomer form. This B-50 cell line was deposited with the ~~American Type Culture Collection~~ AMERICAN TYPE CULTURE COLLECTION depository, 10801 University Boulevard, Manassas, Virginia 20110-2209, on September 18, 1997 under Accession No. CRL-12401 pursuant to the provisions of the Budapest Treaty. However, the present invention is not limited as to the selection of the packaging cell line. - -

Replace the paragraph at page 14, lines 16 – 26 with the following:

- - Alternatively, host cells of the invention may be stably transfected with a rAAV expression cassette of the invention, and with copies of AAV-1 rep and cap genes. Suitable parental cell lines include mammalian cell lines and it may be desirable to select host cells from among non-simian mammalian cells. Examples of suitable parental cell lines include, without limitation, HeLa [ATCC® depository, Accession No. CCL 2], A549 [ATCC® depository, Accession No. CCL 185], KB [CCL 17], Detroit [e.g., Detroit 510, CCL 72] and WI-38 [CCL 75] cells. These cell

lines are all available from the ~~American Type Culture Collection~~ AMERICAN TYPE CULTURE COLLECTION depository, 10801 University Boulevard, Manassas, Virginia 20110-2209. Other suitable parent cell lines may be obtained from other sources and may be used to construct stable cell lines containing the P5 and/or AAV rep and cap sequences of the invention. - -

Amendments to the Claims:

Claims 1 and 2. Currently Cancelled.

Claim 3. Previously canceled.

Claim 4. Currently Cancelled.

Claims 5 – 8. Previously Cancelled.

Claims 9 – 11. Currently Cancelled.

Claims 12 and 13. Previously Cancelled.

Claim 14. Currently Cancelled.

Claim 15. Previously Cancelled.

Claims 16 – 20. Currently Cancelled.

Claims 21 and 22. Previously Cancelled.

Claims 23 – 25. Currently Cancelled.

Claim 26. Previously cancelled.

Claims 27 – 32. Currently cancelled.

33 (Previously Presented). A recombinant virus having an AAV-1 capsid comprising an AAV-1 protein selected from among AAV-1 vp1 having the amino acid sequence of SEQ ID NO:13; AAV-1 vp2 having the amino acid sequence of SEQ ID NO:15 and AAV-1 vp3 having the amino acid sequence of SEQ ID NO:17 and a heterologous molecule which comprises an AAV 5' inverted terminal repeat sequence (ITR), a transgene, and an AAV 3' ITR.

34 (Previously Presented). The recombinant virus according to claim 33, wherein the 5' ITR and 3' ITR are of AAV serotype 2.

35 (Previously Presented). The recombinant virus according to claim 33 further comprising a regulatable promoter which directs expression of the transgene.

36 (Previously Presented). A recombinant host cell transformed with the recombinant virus of claim 33.

Claims 37 – 40. Currently Cancelled.

41 (New). The recombinant virus according to claim 33, wherein said virus comprises an AAV-1 capsid comprising the AAV-1 vp1 having the amino acid sequence of SEQ ID NO:13.

42 (New). The recombinant virus according to claim 33, wherein said virus comprises an AAV-1 capsid comprising the AAV-1 vp2 having the amino acid sequence of SEQ ID NO:15.

43 (New). The recombinant virus according to claim 33, wherein said virus comprises an AAV-1 capsid comprising the AAV-1 vp3 having the amino acid sequence of SEQ ID NO:17.

44 (New). The recombinant virus according to claim 33, wherein the 5' ITR and 3' ITR are of AAV serotype 1.

45 (New). A composition comprising a carrier and a recombinant virus according to claim 33.

REMARKS

Claims 33 – 45 are pending.

Claims 1, 2, 4, 21, 22-25, 27-29, 32 are being cancelled, without prejudice, in order to reduce the issues in this application and expedite allowance thereof.

Cancellation of these claims renders the rejections and objections thereto moot.

Claims 9-11, 14, 17-20, 29, 30, and 37-40 are cancelled as being drawn to non-elected subject matter.

Claims 41 - 45 are new. Claims 41 – 43 are supported on page 8, lines 22-23; page 11, lines 7-11. Claim 44 is supported on page 11, lines 7-11 and page 13, lines 13-14. Claim 45 is supported page 16, lines 9-12.

These amendments are further supported throughout the specification.

No new matter is added by this amendment.

I. Specification

An abstract on a separate sheet is being provided herewith. This abstract is identical to that provided on the cover sheet of the published WO.

The Examiner has noted the improper usage of certain trademarks in the application. Applicants have performed a search and have discovered that ATCC is a trademark of the American Type Cell Culture. The specification has been corrected in the appropriate locations. However, Applicants have been unable to discover any claim that the phrase “American Type Cell Culture” is itself a trademark. In fact, the “American Type Cell Culture” is identified on the organization’s web cite as the owner of a variety of trademarks and the name under which the organization does business.

No new matter is added by this amendment.

II. Election

Applicants note that the restriction requirement has been made final and have cancelled withdrawn claims 9 - 11, 14, 17-20, 29, 30 and 37-40, without prejudice.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/86, 15/35, 5/10, A61K 48/00	A3	(11) International Publication Number: WO 00/28061	(43) International Publication Date: 18 May 2000 (18.05.00)
--	----	---	--

<p>(21) International Application Number: PCT/US99/25694</p> <p>(22) International Filing Date: 2 November 1999 (02.11.99)</p> <p>(30) Priority Data: 60/107,114 5 November 1998 (05.11.98) US</p> <p>(71) Applicant (for all designated States except US): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). XIAO, Weidong [CN/US]; Apartment P4, 155 Washington Lane, Jenkintown, PA 19046 (US).</p> <p>(74) Agents: KODROFF, Cathy, A. et al.; Howson & Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p> <p>(88) Date of publication of the international search report: 3 August 2000 (03.08.00)</p>
--	---

(54) Title: ADENO-ASSOCIATED VIRUS SEROTYPE 1 NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME

(57) Abstract

The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.

(ERROR 3)

Express Mail No. ET033648243US


III. Allowable Subject Matter.

The examiner has indicated that Claims 33-36 are in condition for allowance, because they are free of the prior art of record. A number of claims dependent therefrom have been added.

Applicants believe that the claims are in good condition to pass to issue. The undersigned attorney requests that the examiner telephone if doing so will expedite processing of this application.

No fees are believed to be associated with the filing of this response. However, the Director of the US Patent and Trademark Office is hereby authorized to charge any fee associated with the filing of this paper to deposit account 08-3040.

Respectfully submitted,
HOWSON AND HOWSON
Attorneys for the Applicant

By 
Cathy A. Kodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Phone: (215) 540-9210
Fax: (215) 540-5818

Other aspects and advantages of the invention will be readily apparent to one of skill in the art from the detailed description of the invention.

BRIEF DESCRIPTION OF THE DRAWING

FIGS. 1A–1F illustrate the alignment of nucleotides of AAV-1 [SEQ ID NO: 1], AAV-2 [SEQ ID NO: 18] and AAV-6 [SEQ ID NO: 19]. The alignment was done with MacVector 6.0. The full sequences of AAV-1 are shown in the top line. Nucleotides in AAV-2 and AAV-6 identical to AAV-1 are symbolized by “.” and gaps by “-”. Some of the conserved features among AAVs are marked in this figure. Note the 3' ITRs of AAV-1 and AAV-6 are shown in different orientations.

FIG. 2 illustrates the predicted secondary structure of AAV-1 ITR has been inserted after the word. The nucleotides in AAV-2 and AAV-6 are shown in italic and bold respectively.

FIG. 3A illustrates a hypothesis of how AAV-6 arose from the homologous recombination between AAV-1 and AAV-2. The major elements of AAV-1 are indicated in the graph. A region that is shared between AAV-1, AAV-2 and AAV-6 is shown in box with wavy lines.

FIG. 3B is a detailed illustration of a 71 bp homologous region among AAV-1 has been inserted after the word, AAV-2 has been inserted after the word and AAV-6 has been inserted after the word. Nucleotides that differ among these serotypes are indicated by arrows.

FIG. 4A is a bar chart illustrating expression levels of human alpha 1 anti-trypsin (α 1AT) in serum following delivery of hAAT via recombinant AAV-1 and recombinant AAV-2 viruses.

FIG. 4B is a bar chart illustrating expression levels of erythropoietin (epo) in serum following delivery of the epo gene via recombinant AAV-1 and recombinant AAV-2 viruses.

FIG. 5A is a bar chart illustrating expression levels of α 1AT in liver following delivery of α 1AT as described in Example 7.

FIG. 5B is a bar chart demonstrating expression levels of epo in liver following delivery of epo as described in Example 7.

FIG. 5C is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-1 following delivery of α 1AT or epo to liver as described in Example 7.

FIG. 5D is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-2 following delivery of α 1AT or epo to liver as described in Example 7.

FIG. 6A is a bar chart illustrating expression levels of α 1AT in muscle following delivery of α 1AT as described in Example 7.

FIG. 6B is a bar chart demonstrating expression levels of epo in muscle following delivery of epo as described in Example 7.

FIG. 6C is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-1 following delivery of α 1AT or epo to muscle as described in Example 7.

FIG. 6D is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-2 following delivery of α 1AT or epo to muscle as described in Example 7.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleic acid sequences for an adeno-associated virus of serotype 1

(AAV-1). Also provided are fragments of these AAV-1 sequences. Among particularly desirable AAV-1 fragments are the inverted terminal repeat sequences (ITRs), rep and cap. Each of these fragments may be readily utilized, e.g., as a cassette, in a variety of vector systems and host cells. Such fragments may be used alone, in combination with other AAV-1 sequences or fragments, or in combination with elements from other AAV or non-AAV viral sequences. In one particularly desirable embodiment, a cassette may contain the AAV-1 ITRs of the invention flanking a selected transgene. In another desirable embodiment, a cassette may contain the AAV-1 rep and/or cap proteins, e.g., for use in producing recombinant (rAAV) virus.

Thus, the AAV-1 sequences and fragments thereof are useful in production of rAAV, and are also useful as anti-sense delivery vectors, gene therapy vectors, or vaccine vectors. The invention further provides nucleic acid molecules, gene delivery vectors, and host cells which contain the AAV-1 sequences of the invention. Also provided a novel methods of gene delivery using AAV vectors.

As described herein, the vectors of the invention containing the AAV-1 capsid proteins of the invention are particularly well suited for use in applications in which the neutralizing antibodies diminish the effectiveness of other AAV serotype based vectors, as well as other viral vectors. The rAAV vectors of the invention are particularly advantageous in rAAV readministration and repeat gene therapy.

These and other embodiments and advantages of the invention are described in more detail below. As used throughout this specification and the claims, the term “comprising” is inclusive of other components, elements, integers, steps and the like.

I. AAV-1 Nucleic Acid and Protein Sequences

The AAV-1 nucleic acid sequences of the invention include the DNA sequences of SEQ ID NO: 1 (FIGS. 1A–1F), which consists of 4718 nucleotides. The AAV-1 nucleic acid sequences of the invention further encompass the strand which is complementary to SEQ ID NO: 1, as well as the RNA and cDNA sequences corresponding to SEQ ID NO: 1 and its complementary strand. Also included in the nucleic acid sequences of the invention are natural variants and engineered modifications of SEQ ID NO: 1 and its complementary strand. Such modifications include, for example, labels which are known in the art, methylation, and substitution of one or more of the naturally occurring nucleotides with an analog.

Further included in this invention are nucleic acid sequences which are greater than 85%, preferably at least about 90%, more preferably at least about 95%, and most preferably at least about 98–99% identical or homologous to SEQ ID NO: 1. The term “percent sequence identity” or “identical” in the context of nucleic acid sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over the full-length sequence, or a fragment at least about nine nucleotides, usually at least about 20–24 nucleotides, at least about 28–32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using Fasta, a program in GCG Version 6.1. Fasta provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, 1990, herein incorporated by

See attached
Examiners
Amendment

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Cathy Kodroff on 2/10/04.

The amendment to the specification filed on 4/17/01 was inserted before line 3 of page 1 rather than before line 6 of page 1 as directed.

The term "a" before the word recombinant virus on line 1 of claim 45 has been replaced with the term -- the --.

The term "Figs. 1A-1C" on page 4, line 6 has been replaced with -- Figs. 1A-1F --.

The term "Figs. 1A-1C" on page 6, line 13 has been replaced with -- Figs. 1A-1F --.

The term "Figs. 1A-1C" on page 20, line 13 has been replaced with -- Figs. 1A-1F --.

The term "Figs. 1A-1C" on page 21, line 20 has been replaced with -- Figs. 1A-1F --.

The term "Figs. 1A-1C" on page 22, line 15 has been replaced with -- Figs. 1A-1F --.

The term "Figs. 1A-1C" on page 23, line 15 has been replaced with -- Figs. 1A-1F --.

The term -- (nucleotides 1-143 of SEQ ID NO: 1) -- has been inserted after the word

AAV-1 ITR on line 12 of page 4.

The term -- (nucleotides 438-531 of SEQ ID NO: 1) -- has been inserted after the word

AAV-1 on line 18 of page 4.

The term -- (nucleotides 424-517 of SEQ ID NO: 18) -- has been inserted after the word

AAV-2 on line 19 of page 4.

The term -- (nucleotides 423-516 of SEQ ID NO: 19) -- has been inserted after the word

AAV-6 on line 19 of page 4.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764. The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, SPE - Art Unit 1635, can be reached at (571) 272-0760.

Art Unit: 1635

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Brian Whiteman
Patent Examiner, Group 1635



SCOTT D. PRIEBE, PH.D
PRIMARY EXAMINER

tion may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional [see, e.g., Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2d edit., Cold Spring Harbor Laboratory, New York (1989) and references cited therein] and many such sequences are available from commercial and industrial sources as well as from Genebank.

The selection of the transgene is not a limitation of the present invention. Suitable transgenes may be readily selected from among desirable reporter genes, therapeutic genes, and optionally, genes encoding immunogenic polypeptides. Examples of suitable reporter genes include β -galactosidase (β -gal), an alkaline phosphatase gene, and green fluorescent protein (GFP). Examples of therapeutic genes include, cytokines, growth factors, hormones, and differentiation factors, among others. The transgene may be readily selected by one of skill in the art. See, e.g., WO 98/09657, which identifies other suitable transgenes.

Suitably, the vectors of the invention contain, at a minimum, cassettes which consist of fragments of the AAV-1 sequences and proteins. In one embodiment, a vector of the invention comprises a selected transgene, which is flanked by a 5' ITR and a 3' ITR, at least one of which is an AAV-1 ITR of the invention. Suitably, vectors of the invention may contain a AAV-1 P5 promoter of the invention. In yet another embodiment, a plasmid or vector of the invention contains AAV-1 rep sequences. In still another embodiment, a plasmid or vector of the invention contains at least one of the AAV-1 cap proteins of the invention. Most suitably, these AAV-1-derived vectors are assembled into viral vectors, as described herein.

A. AAV Viral Vectors

In one aspect, the present invention provides a recombinant AAV-1 viral vector produced using the AAV-1 capsid proteins of the invention. The packaged rAAV-1 virions of the invention may contain, in addition to a selected minigene, other AAV-1 sequences, or may contain sequences from other AAV serotypes.

Methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, *J. Virol.*, 70:520-532 (1993) and U.S. Pat. No. 5,478,745. In one suitable method, a selected host cell is provided with the AAV sequence encoding a rep protein, the gene encoding the AAV cap protein and with the sequences for packaging and subsequent delivery. Desirably, the method utilizes the sequences encoding the AAV-1 rep and/or cap proteins of the invention.

In one embodiment, the rep/cap genes and the sequences for delivery are supplied by co-transfection of vectors carrying these genes and sequences. In one currently preferred embodiment, a cis (vector) plasmid, a trans plasmid containing the rep and cap genes, and a plasmid containing the adenovirus helper genes are co-transfected into a suitable cell line, e.g., 293. Alternatively, one or more of these functions may be provided in trans via separate vectors, or may be found in a suitably engineered packaging cell line.

An exemplary cis plasmid will contain, in 5' to 3' order, AAV 5' ITR, the selected transgene, and AAV 3' ITR. In one desirable embodiment, at least one of the AAV ITRs is a 143 nt AAV-1 ITR. However, other AAV serotype ITRs may be readily selected. Suitably, the full-length ITRs are utilized. However, one of skill in the art can readily prepare modified AAV ITRs using conventional techniques. Similarly, methods for construction of such plasmids is well known to those of skill in the art.

A trans plasmid for use in the production of the rAAV-1 virion particle may be prepared according to known techniques. In one desired embodiment, this plasmid contains the rep and cap proteins of AAV-1, or functional fragments thereof. Alternatively, the rep sequences may be from another selected AAV serotype.

The cis and trans plasmid may then be co-transfected with a wild-type helper virus (e.g., Ad2, Ad5, or a herpesvirus), or more desirably, a replication-defective adenovirus, into a selected host cell. Alternatively, the cis and trans plasmid may be co-transfected into a selected host cell together with a transfected plasmid which provides the necessary helper functions. Selection of a suitable host cell is well within the skill of those in the art and include such mammalian cells as 293 cells, HeLa cells, among others.

Alternatively, the cis plasmid and, optionally, the trans plasmid, may be transfected into a packaging cell line which provides the remaining helper functions necessary for production of a rAAV containing the desired AAV-1 sequences of the invention. An example of a suitable packaging cell line, wherein an AAV-2 capsid is desired, is B-50, which stably expresses AAV-2 rep and cap genes under the control of a homologous P5 promoter. This cell line is characterized by integration into the cellular chromosome of multiple copies (at least 5 copies) of P5-rep-cap gene in a concatomer form. This B-50 cell line was deposited with the AMERICAN TYPE CULTURE COLLECTION depository, 10801 University Boulevard, Manassas, Va. 20110-2209, on Sep. 18, 1997 under Accession No. CRL-12401 pursuant to the provisions of the Budapest Treaty. However, the present invention is not limited as to the selection of the packaging cell line.

Exemplary transducing vectors based on AAV-1 capsid proteins have been tested both in vivo and in vitro, as described in more detail in Example 4. In these studies, it was demonstrated that recombinant AAV vector with an AAV-1 virion can transduce both mouse liver and muscle. These, and other AAV-1 based gene therapy vectors which may be generated by one of skill in the art are beneficial for gene delivery to selected host cells and gene therapy patients since the neutralization antibodies of AAV-1 present in much of the human population exhibit different patterns from other AAV serotypes and therefore do not neutralize the AAV-1 virions. One of skill in the art may readily prepare other rAAV viral vectors containing the AAV-1 capsid proteins provided herein using a variety of techniques known to those of skill in the art. One may similarly prepare still other rAAV viral vectors containing AAV-1 sequence and AAV capsids of another serotype.

B. Other Viral Vectors

One of skill in the art will readily understand that the AAV-1 sequences of the invention can be readily adapted for use in these and other viral vector systems for in vivo, ex vivo or in vivo gene delivery. Particularly well suited for use in such viral vector systems are the AAV-1 ITR sequences, the AAV-1 rep, the AAV-1 cap, and the AAV-1 P5 promoter sequences.

For example, in one desirable embodiment, the AAV-1 ITR sequences of the invention may be used in an expression cassette which includes AAV-1 5' ITR, a non-AAV DNA sequences of interest (e.g., a minigene), and 3' ITR and which lacks functional rep/cap. Such a cassette containing an AAV-1 ITR may be located on a plasmid for subsequent transfection into a desired host cell, such as the cis plasmid described above. This expression cassette may further be provided with an AAV capsid of a selected serotype to permit infection of a cell or stably transfected into a desired

gene therapy vectors which may be generated by one of skill in the art are beneficial for gene delivery to selected host cells and gene therapy patients since the neutralization antibodies of AAV-1 present in much of the human population exhibit different patterns from other AAV serotypes and therefore do not neutralize the AAV-1 virions. One of skill in the art may readily prepare other rAAV viral vectors containing the AAV-1 capsid proteins provided herein using a variety of techniques known to those of skill in the art. One may similarly prepare still other rAAV viral vectors containing AAV-1 sequence and AAV capsids of another serotype.

B. Other Viral Vectors

One of skill in the art will readily understand that the AAV-1 sequences of the invention can be readily adapted for use in these and other viral vector systems for *in vitro*, *ex vivo* or *in vivo* gene delivery. Particularly well suited for use in such viral vector systems are the AAV-1 ITR sequences, the AAV-1 rep, the AAV-1 cap, and the AAV-1 P5 promoter sequences.

For example, in one desirable embodiment, the AAV-1 ITR sequences of the invention may be used in an expression cassette which includes AAV-1 5' ITR, a non-AAV DNA sequences of interest (e.g., a minigene), and 3' ITR and which lacks functional rep/cap. Such a cassette containing an AAV-1 ITR may be located on a plasmid for subsequent transfection into a desired host cell, such as the cis plasmid described above. This expression cassette may further be provided with an AAV capsid of a selected serotype to permit infection of a cell or stably transfected into a desired host cell for packaging of rAAV virions. Such an expression cassette may be readily adapted for use in other viral systems, including adenovirus systems and lentivirus systems. Methods of producing Ad/AAV vectors are well known to those of skill in the art. One desirable method is described in PCT/US95/14018. However, the present invention is not limited to any particular method.

Another aspect of the present invention is the novel AAV-1 P5 promoter sequences which are located in the region spanning nt 236 - 299 of SEQ ID NO: 1. This promoter is useful in a variety of viral vectors for driving expression of a desired transgene.

host cell for packaging of rAAV virions. Such an expression cassette may be readily adapted for use in other viral systems, including adenovirus systems and lentivirus systems. Methods of producing Ad/AAV vectors are well known to those of skill in the art. One desirable method is described in PCT/US95/14018. However, the present invention is not limited to any particular method.

Another aspect of the present invention is the novel AAV-1 P5 promoter sequences which are located in the region spanning nt 236-299 of SEQ ID NO: 1. This promoter is useful in a variety of viral vectors for driving expression of a desired transgene.

Similarly, one of skill in the art can readily select other fragments of the AAV-1 genome of the invention for use in a variety of vector systems. Such vector systems may include, e.g., lentiviruses, retroviruses, poxviruses, vaccinia viruses, and adenoviral systems, among others. Selection of these vector systems is not a limitation of the present invention.

C. Host Cells and Packaging Cell Lines

In yet another aspect, the present invention provides host cells which may be transiently transfected with AAV-1 nucleic acid sequences of the invention to permit expression of a desired transgene or production of a rAAV particle. For example, a selected host cell may be transfected with the AAV-1 P5 promoter sequences and/or the AAV-1 5' ITR sequences using conventional techniques. Providing AAV helper functions to the transfected cell lines of the invention results in packaging of the rAAV as infectious rAAV particles. Such cell lines may be produced in accordance with known techniques [see, e.g., U.S. Pat. No. 5,658,785], making use of the AAV-1 sequences of the invention.

Alternatively, host cells of the invention may be stably transfected with a rAAV expression cassette of the invention, and with copies of AAV-1 rep and cap genes. Suitable parental cell lines include mammalian cell lines and it may be desirable to select host cells from among non-simian mammalian cells. Examples of suitable parental cell lines include, without limitation, HeLa [ATCC® depositary, Accession No. CCL 2], A549 [ATCC® depositary, Accession No. CCL 185], KB [CCL 17], Detroit [e.g., Detroit 510, CCL 72] and WI-38 [CCL 75] cells. These cell lines are all available from the AMERICAN TYPE CULTURE COLLECTION depositary, 10801 University Boulevard, Manassas, Va. 20110-2209/10801 University Boulevard, Manassas, Va. 20110-2209 USA. Other suitable parent cell lines may be obtained from other sources and may be used to construct stable cell lines containing the P5 and/or AAV rep and cap sequences of the invention.

Recombinant vectors generated as described above are useful for delivery of the DNA of interest to cells.

III Methods of Delivering Genes via AAV-1 Derived Vectors

In another aspect, the present invention provides a method for delivery of a transgene to a host which involves transfecting or infecting a selected host cell with a recombinant viral vector generated with the AAV-1 sequences (or functional fragments thereof) of the invention. Methods for delivery are well known to those of skill in the art and are not a limitation of the present invention.

In one desirable embodiment, the invention provides a method for AAV-mediated delivery of a transgene to a host. This method involves transfecting or infecting a selected host cell with a recombinant viral vector containing a selected transgene under the control of sequences which direct expression thereof and AAV-1 capsid proteins.

Optionally, a sample from the host may be first assayed for the presence of antibodies to a selected AAV serotype. A variety of assay formats for detecting neutralizing antibodies are well known to those of skill in the art. The selection of such an assay is not a limitation of the present invention. See, e.g., Fisher et al, *Nature Med.*, 3(3):306-312 (March 1997) and W. C. Manning et al, *Human Gene Therapy*, 9:477-485 (Mar. 1, 1998). The results of this assay may be used to determine which AAV vector containing capsid proteins of a particular serotype are preferred for delivery, e.g., by the absence of neutralizing antibodies specific for that capsid serotype.

In one aspect of this method, the delivery of vector with AAV-1 capsid proteins may precede or follow delivery of a gene via a vector with a different serotype AAV capsid protein. Thus, gene delivery via rAAV vectors may be used for repeat gene delivery to a selected host cell. Desirably, subsequently administered rAAV vectors carry the same transgene as the first rAAV vector, but the subsequently administered vectors contain capsid proteins of serotypes which differ from the first vector. For example, if a first vector has AAV-2 capsid proteins, subsequently administered vectors may have capsid proteins selected from among the other serotypes, including AAV-1, AAV-3A, AAV-3B, AAV-4 and AAV-6.

Thus, a rAAV-1-derived recombinant viral vector of the invention provides an efficient gene transfer vehicle which can deliver a selected transgene to a selected host cell in vivo or ex vivo even where the organism has neutralizing antibodies to one or more AAV serotypes. These compositions are particularly well suited to gene delivery for therapeutic purposes. However, the compositions of the invention may also be useful in immunization. Further, the compositions of the invention may also be used for production of a desired gene product in vitro.

The above-described recombinant vectors may be delivered to host cells according to published methods. An AAV viral vector bearing the selected transgene may be administered to a patient, preferably suspended in a biologically compatible solution or pharmaceutically acceptable delivery vehicle. A suitable vehicle includes sterile saline. Other aqueous and non-aqueous isotonic sterile injection solutions and aqueous and non-aqueous sterile suspensions known to be pharmaceutically acceptable carriers and well known to those of skill in the art may be employed for this purpose.

The viral vectors are administered in sufficient amounts to transfect the cells and to provide sufficient levels of gene transfer and expression to provide a therapeutic benefit without undue adverse effects, or with medically acceptable physiological effects, which can be determined by those skilled in the medical arts. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to the liver, oral, intranasal, intravenous, intramuscular, subcutaneous, intradermal, and other parental routes of administration. Routes of administration may be combined, if desired.

Dosages of the viral vector will depend primarily on factors such as the condition being treated, the age, weight and health of the patient, and may thus vary among patients. For example, a therapeutically effective human dosage of the viral vector is generally in the range of from about 1 ml to about 100 ml of solution containing concentrations of from about 1×10^9 to 1×10^{16} genomes virus vector. A preferred human dosage may be about 1×10^{13} to 1×10^{16} AAV genomes. The dosage will be adjusted to balance the therapeutic benefit against any side effects and such dosages may

Similarly, one of skill in the art can readily select other fragments of the AAV-1 genome of the invention for use in a variety of vector systems. Such vector systems may include, e.g., lentiviruses, retroviruses, poxviruses, vaccinia viruses, and adenoviral systems, among others. Selection of these vector systems is not a
5 limitation of the present invention.

C. Host Cells And Packaging Cell Lines

In yet another aspect, the present invention provides host cells which may be transiently transfected with AAV-1 nucleic acid sequences of the invention to permit expression of a desired transgene or production of a rAAV particle. For
10 example, a selected host cell may be transfected with the AAV-1 P5 promoter sequences and/or the AAV-1 5' ITR sequences using conventional techniques. Providing AAV helper functions to the transfected cell lines of the invention results in packaging of the rAAV as infectious rAAV particles. Such cell lines may be produced in accordance with known techniques [see, e.g., US Patent No. 5,658,785], making
15 use of the AAV-1 sequences of the invention.

Alternatively, host cells of the invention may be stably transfected with a rAAV expression cassette of the invention, and with copies of AAV-1 rep and cap genes. Suitable parental cell lines include mammalian cell lines and it may be desirable to select host cells from among non-simian mammalian cells. Examples of suitable
20 parental cell lines include, without limitation, HeLa [ATCC CCL 2], A549 [ATCC Accession No. CCL 185], KB [CCL 17], Detroit [e.g., Detroit 510, CCL 72] and WI-38 [CCL 75] cells. These cell lines are all available from the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 USA. Other suitable parent cell lines may be obtained from other sources and may be used to
25 construct stable cell lines containing the P5 and/or AAV rep and cap sequences of the invention.

Recombinant vectors generated as described above are useful for delivery of the DNA of interest to cells.

NAB titers were analyzed by assessing the ability of serum antibody to inhibit the transduction of reporter virus expressing green fluorescent protein (GFP) (AAV1-GFP or AAV2-GFP) into 84-31 cells. Various dilutions of antibodies preincubated with reporter virus for 1 hour at 37° C. were added to 90% confluent cell cultures. Cells were incubated for 48 hours and the expression of green fluorescent protein was measured by Fluorolmaging (Molecular Dynamics). NAB titers were calculated as the highest dilution at which 50% of the cells stained green.

Analysis of NAB in rhesus monkeys showed that 61% of animals tested positive for AAV-1; a minority (24%) has NAB to AAV-2. Over one-third of animals had antibodies to AAV-1 but not AAV-2 (i.e., were monospecific for AAV-1), whereas no animals were positive for AAV-2 without reacting to AAV-1. These data support the hypothesis that AAV-1 is endemic in rhesus monkeys. The presence of true AAV-2 infections in this group of nonhuman primates is less clear, since cross-neutralizing activity of an AAV-1 response to AAV-2 can not be ruled out. It is interesting that there is a linear relationship between AAV-2 NAB and AAV-1 NAB in animals that had both.

B. Humans

For these neutralization antibody assays, human serum samples were incubated at 56° C. for 30 min to inactivate complement and then diluted in DMEM. The virus (rAAV or rAd with either lacZ or GFP) was then mixed with each serum dilution (20x, 400x, 2000x, 4000x, etc.) and incubated for 1 hour at 37° C. before applied to 90% confluent cultures of 84-31 cells (for AAV) or Hela cells (for adenovirus) in 96-well plates. After 60 minutes of incubation at culture condition, 100 µl additional media containing 20% FCS was added to make final culture media containing 10% FCS.

The result is summarized in Table 3.

TABLE 3

Adenovirus	AAV-1	AAV-2	# of samples	Percentage
-	-	-	41	53.2%
+	-	-	16	20.8%
-	+	-	0	0.0%
-	-	+	2	2.6%
-	+	+	2	2.6%
+	-	+	3	3.9%
+	+	-	0	0.0%
+	+	+	13	16.9%
Total			77	100%

The human neutralizing antibodies against these three viruses seemed to be unrelated since the existence of neutralizing antibodies against AAV are not indications for antibodies against adenovirus. However, AAV requires adenovirus as helper virus, in most of the cases, the neutralizing antibodies against AAV correlated with the existence of neutralizing antibodies to adenovirus. Among the 77 human serum samples screened, 41% of the samples can neutralize the infectivity of recombinant adenovirus based on Ad5. 15/77 (19%) of serum samples can neutralize the transduction of rAAV-1 while 20/77 (20%) of the samples inhibit rAAV-2 transduction at 1 to 80 dilutions or higher. All serum samples positive in neutralizing antibodies for AAV-1 in are also positive for AAV-2. However, there are five (6%) rAAV-2 positive samples that failed to neutralize rAAV-1. In samples that are positive for neutralizing antibodies, the titer of antibodies also varied in the positive ones. The results from screening human sera for antibodies against AAVs supported the conclusion that AAV-1 presents the same

epitome as that of AAV-2 to interact with cellular receptors since AAV-1 neutralizing human serums can also decrease the infectivity of AAV-2. However, the profile of neutralizing antibodies for these AAVs is not identical, there are additional specific receptors for each AAV serotype.

EXAMPLE 6

Recombinant AAV Viruses Exhibit Tissue Tropism

The recombinant AAV-1 vectors of the invention and the recombinant AAV-2 vectors [containing the gene encoding human α 1-antitrypsin (α 1AT) or murine erythropoietin (Epo) from a cytomegalovirus-enhanced β -actin promoter (CB)] were evaluated in a direct comparison to equivalent copies of AAV-2 vectors containing the same vector genes.

Recombinant viruses with AAV-1 capsids were constructed using the techniques in Example 1. To make rAAV with AAV-1 virions, pAV1H or p5E18 (2/1) was used as the trans plasmid to provide Rep and Cap functions. For the generation of the rAAV based on AAV-2, p5E18(2/2) was used as the trans plasmid, since it greatly improved the rAAV yield. [Early experiments indicated similar in vivo performances of AAV-1 vectors produced with pAV1H and p5E19 (2/1). All subsequent studies used AAV-1 vectors derived from p5E18(2/1) because of the increased yield.]

Equivalent stocks of the AAV-1 and AAV-2 vectors were injected intramuscularly (5×10^1 genomes) or liver via the portal circulation (1×10^{11} genomes) into immunodeficient mice, and the animals (four groups) were analyzed on day 30 for expression of transgene. See, FIGS. 4A and 4B.

AAV-2 vectors consistently produced 10- to 50-fold more serum erythropoietin or α 1-antitrypsin when injected into liver compared to muscle. (However, the AAV-1-delivered genes did achieve acceptable expression levels in the liver.) This result was very different from that for AAV-1 vectors, with which muscle expression was equivalent to or greater than liver expression. In fact, AAV-1 outperformed AAV-2 in muscle when equivalent titers based on genomes were administered.

EXAMPLE 7

Gene Delivery via rAAV-1

C57BL/6 mice (6- to 8-week old males, Jackson Laboratories) were analyzed for AAV mediated gene transfer to liver following intrasplenic injection of vector (i.e., targeted to liver). A total of 10^{11} genome equivalents of rAAV-1 or rAAV-2 vector were injected into the circulation in 100 µl buffered saline. The first vector contained either an AAV-1 capsid or an AAV-2 capsid and expressed α 1AT under the control of the chicken β -actin (CB) promoter. Day 28 sera were analyzed for antibodies against AAV-1 or AAV-2 and serum α 1AT levels were checked. Animals were then injected with an AAV-1 or AAV-2 construct expressing erythropoietin (Epo, also under the control of the CB promoter). One month later sera was analyzed for serum levels of Epo. The following groups were analyzed (FIGS. 5A-5D).

In Group 1, vector 1 was AAV-2 expressing α 1AT and vector 2 was AAV-2 expressing Epo. Animals generated antibodies against AAV-2 following the first vector administration which prevented the readministration of the AAV-2 based vector. There was no evidence for cross-neutralizing the antibody to AAV-1.

In Group 2, vector 1 was AAV-1 expressing α 1AT while vector 2 was AAV-1 expressing Epo. The first vector admin-

with cellular receptors since AAV-1 neutralizing human serums can also decrease the infectivity of AAV-2. However, the profile of neutralizing antibodies for these AAVs is not identical, there are additional specific receptors for each AAV serotype.

Example 6 - Recombinant AAV Viruses Exhibit Tissue Tropism

5 The recombinant AAV-1 vectors of the invention and the recombinant AAV-2 vectors [containing the gene encoding human α 1-antitrypsin (α 1AT) or murine erythropoietin (Epo) from a cytomegalovirus-enhanced β -actin promoter (CB)] were evaluated in a direct comparison to equivalent copies of AAV-2 vectors containing the same vector genes.

10 Recombinant viruses with AAV-1 capsids were constructed using the techniques in Example 1. To make rAAV with AAV-1 virions, pAV1H or p5E18 (2/1) was used as the *trans* plasmid to provide Rep and Cap functions. For the generation of the rAAV based on AAV-2, p5E18(2/2) was used as the *trans* plasmid, since it greatly improved the rAAV yield. [Early experiments indicated similar *in vivo*
15 performances of AAV-1 vectors produced with pAV1H and p5E19 (2/1). All subsequent studies used AAV-1 vectors derived from p5E18(2/1) because of the increased yield.]

 Equivalent stocks of the AAV-1 and AAV-2 vectors were injected intramuscularly (5×10^{10} genomes) or liver via the portal circulation (1×10^{11}
20 genomes) into immunodeficient mice, and the animals (four groups) were analyzed on day 30 for expression of transgene. See, Figs. 4A and 4B.

 AAV-2 vectors consistently produced 10- to 50-fold more serum erythropoietin or α 1-antitrypsin when injected into liver compared to muscle. (However, the AAV-1-delivered genes did achieve acceptable expression levels in the
25 liver.) This result was very different from that for AAV-1 vectors, with which muscle expression was equivalent to or greater than liver expression. In fact, AAV-1 outperformed AAV-2 in muscle when equivalent titers based on genomes were administered.

-continued

```

aggagagcgc cggagcttca aacactgcat tggacaatgt catgatcaca gacgaagagg 3900
aatcaaagc cactaaccac gtggccaccg aaagatttgg gactgtggca gtcaatctcc 3960
agagcagcag cacagaccct gcgaccggag atgtgcatgt tatgggagcc ttacctggaa 4020
tggtgtggca agacagagac gtatacctgc agggctctat ttggggcaaa attcctcaca 4080
cggatggaca ctttcaccgc tctcctctca tgggcggctt tggacttaag caccgcctc 4140
ctcagatcct catcaaaaac acgcctgttc ctgcgaatcc tccggcagag ttttcggcta 4200
caaagtgtgc ttcattcctc acccagtatt ccacaggaca agtgagcgtg gagattgaat 4260
gggagctgca gaaagaaaac agcaaacgct ggaatcccg agtgcagtat acatctaact 4320
atgcaaaatc tgccaacgct gatttcactg tggacaacaa tggactttat actgagcctc 4380
gccccattgg caccgcgtac ctccaccgct ccctgtaatt gtgtgttaat caataaacg 4440
gttaattcgt gtcagttgaa ctttggcttc atgtccttat tatcttatct ggtcaccata 4500
gcaaccggtt acacattaac tgcttagttg cgttcgcga ataccctag tgatggagtt 4560
gcccactccc tctatgcgcg ctgcctcgtt cgggtggggc ggcagagcag agctctgccg 4620
tctgcccacc tttggtccgc agggcccacc gagcgagcga gcgcgcatag agggagtggc 4680
caa 4683

```

<210> SEQ ID NO 20
 <211> LENGTH: 16
 <212> TYPE: DNA
 <213> ORGANISM: rep binding motif

<400> SEQUENCE: 20

gctcgtcgc tgcgtg

16

What is claimed is:

1. A recombinant virus having an AAV-1 capsid comprising an AAV-1 protein selected from among AAV-1 vp1 having the amino acid sequence of SEQ ID NO:13; AAV-1 vp2 having the amino acid sequence of SEQ ID NO:15 and AAV-1 vp3 having the amino acid sequence of SEQ ID NO:17 and a heterologous molecule which comprises an AAV 5' inverted terminal repeat sequence (ITR), a transgene, and an AAV 3' ITR.
2. The recombinant virus according to claim 1, wherein the 5' ITR and 3' ITR are of AAV serotype 2.
3. The recombinant virus according to claim 1 further comprising a regulatable promoter which directs expression of the transgene.
4. A recombinant host cell transformed with the recombinant virus of claim 1.

5. The recombinant virus according to claim 1, wherein said virus comprises an AAV-1 capsid comprising the AAV-1 vp1 having the amino acid sequence of SEQ ID NO:13.
6. The recombinant virus according to claim 1, wherein said virus comprises an AAV-1 capsid comprising the AAV-1 vp2 having the amino acid sequence of SEQ ID NO:15.
7. The recombinant virus according to claim 1, wherein said virus comprises an AAV-1 capsid comprising the AAV-1 vp3 having the amino acid sequence of SEQ ID NO:17.
8. The recombinant virus according to claim 1, wherein the 5' ITR and 3' ITR are of AAV serotype 1.
9. A composition comprising a carrier and the recombinant virus according to claim 1.

* * * * *

See page 2 of preliminary Amendment. (Attached)

09/807,802
GNVPN.031US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1635
)
James M. Wilson et al) Examiner: B. Whiteman
)
Appln. No. 09/807,802)
)
Filed: November 29, 2001)
)
For: ADENO-ASSOCIATED VIRUS)
SEROTYPE I NUCLEIC ACID)
SEQUENCES, VECTORS AND HOST)
CELLS CONTAINING SAME)

Assistant Commissioner for Patents
Washington, DC 20231

THIRD PRELIMINARY AMENDMENT

Sir:

Please amend the application as set forth below.

In the Claims

Kindly add new claims 33 - 40.

CERTIFICATE OF TRANSMISSION under 37 CFR 1.8
I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office
on December 31, 2002.

Signature

Cathy A. Kodroff

Cathy A. Kodroff

Typed or printed name of person signing Certificate



00270

PATENT TRADEMARK OFFICE

33. A recombinant virus having an AAV-1 capsid comprising an AAV-1 protein selected from among AAV-1 vp1 having the amino acid sequence of SEQ ID NO:13; AAV-1 vp2 having the amino acid sequence of SEQ ID NO:15 and AAV-1 vp3 having the amino acid sequence of SEQ ID NO:17 and a heterologous molecule which comprises an AAV 5' inverted terminal repeat sequence (ITR), a transgene, and an AAV 3' ITR.

34. The recombinant virus according to claim 33, wherein the 5' ITR and 3' ITR are of AAV serotype 2.

35. The recombinant virus according to claim 33 further comprising a regulatable promoter which directs expression of the transgene.

36. A recombinant host cell transformed with the recombinant virus of claim 33.

37. A recombinant host cell transformed with a nucleic acid sequence expressing one or more AAV-1 rep proteins selected from among rep78 having the amino acid sequence of SEQ ID NO:5, rep 68 having the amino acid sequence of SEQ ID NO:7, rep 52 having the amino acid sequence of SEQ ID NO: 9, and rep 40 having the amino acid sequence of SEQ ID NO:11.

38. A recombinant host cell transformed with a nucleic acid sequence expressing one or more AAV-1 cap proteins selected from among vp1 having the amino acid sequence of SEQ ID NO:13, vp2 having the amino acid sequence of SEQ ID NO: 15 and vp3 having the amino acid sequence of SEQ ID NO:17.

39. A method for transducing a muscle cell, said method comprising the step of infecting the cell with a recombinant AAV vector comprising an AAV1 capsid.

40. A method for transducing a liver cell, said method comprising the step of infecting the cell with a recombinant AAV vector comprising an AAV1 capsid.

REMARKS


After entry of this preliminary amendment, the pending claims are claims 1-6, 9-11, 14, 16-20, and 23 - 40.

New claims 33 - 40 are supported on page 9, lines 22; page 11, lines 7-11; page 14, lines 6-8 and 16-18; page 24, lines 18-20; Example 4, page 26, lines 2 - 11 and Example 6, page 29, lines 25 - 28, and throughout the specification. No new matter is introduced by this preliminary amendment.

Attached hereto is a clean copy of the claims as amended by this paper.

Applicants hereby authorize the additional claim fees to be charged to Deposit Account No. 08-3040. Additionally, the Director of the U. S. Patent and Trademark Office is hereby authorized to charge any other fees due with the filing of this paper to Deposit Account No. 08-3040.

Respectfully submitted,
HOWSON AND HOWSON
Attorneys for Applicants

By 
Cathy A. Kodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818

FAX

HOWSON AND HOWSON
Spring House Corporate Center
Box 457
Spring House, PA 19477

TO: Group Art Unit 1635

DATE: December 31, 2002

REFERENCE: US Patent Application No. 09/807,802

NUMBER OF PAGES (INCLUDING COVER SHEET): 12

FAX NUMBER OF RECIPIENT: (703) 308-4242

Dear Sirs:


OFFICIAL

Enclosed is a twelve page submission, composed of a Third Preliminary Amendment (4 pages), a clean copy of the pending claims (6 pages); a fee transmittal form (1 page); and this transmittal cover sheet (1 page)


Respectfully submitted,
HOWSON AND HOWSON

CERTIFICATE OF TRANSMISSION under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on December 31, 2002.



Signature

By: 
Cathy A. Kodroff
Registration No. 33,980

Cathy A. Kodroff

Typed or printed name of person signing Certificate

The information contained in this fax message and any accompanying pages is intended only for the personal and confidential use of the designated recipient(s). This may be privileged attorney-client communication. If you are not a designated recipient or an agent responsible for delivery of this message, you have received this document in error, and any review, dissemination, distribution, use or copying is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, e-mail or return fax, and return the original by mail. Thank you.

FAX: (215) 540-5818
E-MAIL: howson3@aol.com
PHONE: (215) 540-9210 - CATHY A. KODROFF



00270

PATENT TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 564.00

Complete If Known

Application Number	09/807,802
Filing Date	11/29/2001
First Named Inventor	James M. Wilson et al
Examiner Name	B. Whiteman
Group Art Unit	1635
Attorney Docket No.	GNVPN.031US

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit
Account
Number

08-3040

Deposit
Account
Name

HOWSON AND HOWSON

- ☒ Charge Any Additional Fee Required
Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status.
See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money
Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Fee Fee Fee Fee Description
Code (\$) Code (\$)

101	740	201	370	Utility filing fee
106	330	206	165	Design filing fee
107	510	207	255	Plant filing fee
108	740	208	370	Reissue filing fee
114	160	214	80	Provisional filing fee

Fee Paid

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES

Total Claims 33
Independent Claims 15
Multiple Dependent

25 Extra Claims
80** = 8 x 18.00 = 144.00
10** = 5 x 84.00 = 420.00

Fee from below
Fee Paid

Large Entity Small Entity

Fee	Fee	Fee	Fee	Fee Description
Code	(\$)	Code	(\$)	
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 564.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	
118 1,440	218 720	Extension for reply within fourth month	
128 1,960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	*
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(c)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
179 740	279 370	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type) Cathy A. kodroff

Registration No. 33,980
(Attorney/Agent)

Complete (if applicable)

Telephone 215-540-9200

Signature

Cathy A. Kodroff

Date 12/31/2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



00270

PATENT TRADEMARK OFFICE